Cargando…
A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan
BACKGROUND: Since June 2013, Japan has suspended proactive recommendation of human papillomavirus (HPV) vaccination due to self-reported diverse symptoms, including pain and motor dysfunction, as possible serious adverse events following immunization. Although these symptoms may be seen in adolescen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Epidemiological Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666311/ https://www.ncbi.nlm.nih.gov/pubmed/34719583 http://dx.doi.org/10.2188/jea.JE20210277 |
_version_ | 1784614181200199680 |
---|---|
author | Fukushima, Wakaba Hara, Megumi Kitamura, Yuri Shibata, Masahiko Ugawa, Yoshikazu Hirata, Koichi Oka, Akira Miyamoto, Shinya Kusunoki, Susumu Kuwabara, Satoshi Hashimoto, Shuji Sobue, Tomotaka |
author_facet | Fukushima, Wakaba Hara, Megumi Kitamura, Yuri Shibata, Masahiko Ugawa, Yoshikazu Hirata, Koichi Oka, Akira Miyamoto, Shinya Kusunoki, Susumu Kuwabara, Satoshi Hashimoto, Shuji Sobue, Tomotaka |
author_sort | Fukushima, Wakaba |
collection | PubMed |
description | BACKGROUND: Since June 2013, Japan has suspended proactive recommendation of human papillomavirus (HPV) vaccination due to self-reported diverse symptoms, including pain and motor dysfunction, as possible serious adverse events following immunization. Although these symptoms may be seen in adolescents without HPV vaccination, their frequency, taking into account disease severity, has not been examined. METHODS: A two-stage, descriptive, nationwide epidemiological survey was conducted in 2016, with a 6-month target period from July 1 to December 31, 2015, to estimate the prevalence and incidence of diverse symptoms among Japanese adolescents without HPV vaccination. Participants were 11,037 medical departments in hospitals selected nationwide by stratified random sampling. Eligible patients had to satisfy four criteria: (1) aged 12–18 years upon visiting hospital; (2) having at least one of four symptoms/disorders (pain or sensory dysfunction, motor dysfunction, autonomic dysfunction, or cognitive impairment); (3) symptoms/disorders persisting for at least 3 months; and (4) both criteria (2) and (3) influence attendance at school or work. We then extracted data of patients with diverse symptoms similar to those after HPV vaccination while considering opinions of doctors in charge. RESULTS: Estimated 6-month period prevalence of diverse symptoms among girls aged 12–18 years without HPV vaccination was 20.2 per 100,000. Annual incidence was estimated to be 7.3 per 100,000. CONCLUSION: Adolescent Japanese girls without HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination. Our findings predict the medical demands for coincident diverse symptoms, which are temporally associated with but not caused by HPV vaccination of Japanese adolescents. |
format | Online Article Text |
id | pubmed-8666311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japan Epidemiological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-86663112022-01-05 A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan Fukushima, Wakaba Hara, Megumi Kitamura, Yuri Shibata, Masahiko Ugawa, Yoshikazu Hirata, Koichi Oka, Akira Miyamoto, Shinya Kusunoki, Susumu Kuwabara, Satoshi Hashimoto, Shuji Sobue, Tomotaka J Epidemiol Original Article BACKGROUND: Since June 2013, Japan has suspended proactive recommendation of human papillomavirus (HPV) vaccination due to self-reported diverse symptoms, including pain and motor dysfunction, as possible serious adverse events following immunization. Although these symptoms may be seen in adolescents without HPV vaccination, their frequency, taking into account disease severity, has not been examined. METHODS: A two-stage, descriptive, nationwide epidemiological survey was conducted in 2016, with a 6-month target period from July 1 to December 31, 2015, to estimate the prevalence and incidence of diverse symptoms among Japanese adolescents without HPV vaccination. Participants were 11,037 medical departments in hospitals selected nationwide by stratified random sampling. Eligible patients had to satisfy four criteria: (1) aged 12–18 years upon visiting hospital; (2) having at least one of four symptoms/disorders (pain or sensory dysfunction, motor dysfunction, autonomic dysfunction, or cognitive impairment); (3) symptoms/disorders persisting for at least 3 months; and (4) both criteria (2) and (3) influence attendance at school or work. We then extracted data of patients with diverse symptoms similar to those after HPV vaccination while considering opinions of doctors in charge. RESULTS: Estimated 6-month period prevalence of diverse symptoms among girls aged 12–18 years without HPV vaccination was 20.2 per 100,000. Annual incidence was estimated to be 7.3 per 100,000. CONCLUSION: Adolescent Japanese girls without HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination. Our findings predict the medical demands for coincident diverse symptoms, which are temporally associated with but not caused by HPV vaccination of Japanese adolescents. Japan Epidemiological Association 2022-01-05 /pmc/articles/PMC8666311/ /pubmed/34719583 http://dx.doi.org/10.2188/jea.JE20210277 Text en © 2021 Wakaba Fukushima et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Article Fukushima, Wakaba Hara, Megumi Kitamura, Yuri Shibata, Masahiko Ugawa, Yoshikazu Hirata, Koichi Oka, Akira Miyamoto, Shinya Kusunoki, Susumu Kuwabara, Satoshi Hashimoto, Shuji Sobue, Tomotaka A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title | A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title_full | A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title_fullStr | A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title_full_unstemmed | A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title_short | A Nationwide Epidemiological Survey of Adolescent Patients With Diverse Symptoms Similar to Those Following Human Papillomavirus Vaccination: Background Prevalence and Incidence for Considering Vaccine Safety in Japan |
title_sort | nationwide epidemiological survey of adolescent patients with diverse symptoms similar to those following human papillomavirus vaccination: background prevalence and incidence for considering vaccine safety in japan |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666311/ https://www.ncbi.nlm.nih.gov/pubmed/34719583 http://dx.doi.org/10.2188/jea.JE20210277 |
work_keys_str_mv | AT fukushimawakaba anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT haramegumi anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kitamurayuri anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT shibatamasahiko anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT ugawayoshikazu anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT hiratakoichi anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT okaakira anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT miyamotoshinya anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kusunokisusumu anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kuwabarasatoshi anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT hashimotoshuji anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT sobuetomotaka anationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT fukushimawakaba nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT haramegumi nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kitamurayuri nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT shibatamasahiko nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT ugawayoshikazu nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT hiratakoichi nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT okaakira nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT miyamotoshinya nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kusunokisusumu nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT kuwabarasatoshi nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT hashimotoshuji nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan AT sobuetomotaka nationwideepidemiologicalsurveyofadolescentpatientswithdiversesymptomssimilartothosefollowinghumanpapillomavirusvaccinationbackgroundprevalenceandincidenceforconsideringvaccinesafetyinjapan |